-transparent.png){kind=logo}
Thirty-two evaluable patients with advanced epithelial ovarian cancer were treated with aminothiadiazole at a dosage of 125 mg/m2 weekly. Two patients had partial responses, 12 had stable disease, 16 had increasing disease, and two were inevaluable for response. Aminothiadiazole used in this dosage and schedule has minimal activity in ovarian carcinoma patients previously treated.
Related Publications
R F Asbury, and
J Wilson, and
J A Blessing, and
H J Buchsbaum, and
P J DiSaia
August 1987,
American journal of clinical oncology,
R F Asbury, and
J Wilson, and
J A Blessing, and
H J Buchsbaum, and
P J DiSaia
February 1990,
American journal of clinical oncology,
R F Asbury, and
J Wilson, and
J A Blessing, and
H J Buchsbaum, and
P J DiSaia
October 1989,
American journal of clinical oncology,
R F Asbury, and
J Wilson, and
J A Blessing, and
H J Buchsbaum, and
P J DiSaia
October 1987,
American journal of clinical oncology,
R F Asbury, and
J Wilson, and
J A Blessing, and
H J Buchsbaum, and
P J DiSaia
December 1984,
American journal of clinical oncology,
R F Asbury, and
J Wilson, and
J A Blessing, and
H J Buchsbaum, and
P J DiSaia
June 1984,
American journal of clinical oncology,
R F Asbury, and
J Wilson, and
J A Blessing, and
H J Buchsbaum, and
P J DiSaia
August 1985,
American journal of clinical oncology,
R F Asbury, and
J Wilson, and
J A Blessing, and
H J Buchsbaum, and
P J DiSaia
August 1990,
American journal of clinical oncology,
R F Asbury, and
J Wilson, and
J A Blessing, and
H J Buchsbaum, and
P J DiSaia
January 1986,
Investigational new drugs,
R F Asbury, and
J Wilson, and
J A Blessing, and
H J Buchsbaum, and
P J DiSaia
November 1990,
Investigational new drugs,
